HRMY

32.5901.18%
AS

Andrew Serafin

Executive VP & Chief Strategy Officer

Mr. Andrew Serafin, JD, MBA, serves as Executive Vice President and Chief Strategy Officer at Harmony Biosciences, LLC. He serves as an Executive Vice President and Chief Strategy Officer of Harmony Biosciences Holdings, Inc. since January 2021 and served its Chief Business Officer from December 2018 to January 2021 and was its Senior Vice President of Business Development & Corporate Strategy from September 2017 to December 2018. He is responsible for leading the company’s corporate strategy, business and corporate development initiatives, and alliance management efforts, including the expansion of the company’s pipeline through the acquisition and licensing of novel rare disease therapies for patients with high, unmet needs. Mr. Serafin serves as a Chief Strategy Officer at Harmony Biosciences, LLC., since 2021. Mr. Serafin served as a Chief Business Officer at Harmony Biosciences, LLC., until 2021. Mr. Serafin served as Vice President of Business Development at Marathon Pharmaceuticals, LLC from August 2015 to May 2017. Mr. Serafin was responsible for leading Marathon’s business development efforts, including the acquisition and in-licensing of new rare disease treatments into its pipeline. Mr. Serafin has many years’ experience in corporate legal counseling and mergers and acquisitions in the healthcare and technology sectors, including nine years of specialty pharmaceutical experience. He served as Vice President for M&A and legal affairs at AltaThera Pharmaceuticals and as Vice President of U.S. legal affairs and Associate General Counsel at Lundbeck Inc., from July 2006 to March 2015. Mr. Serafin began his career in private legal practice where he specialized in corporate transactions, provided strategic consulting and consummated both public and private deals, acquisitions and divestitures. He holds a Bachelor of Science degree from the University of Illinois, a Juris Doctor from the Loyola University Chicago School of Law, and a Masters of Business Administration from the Northwestern University Kellogg School of Management. He was General Counsel of AltaThera Pharmaceuticals, LLC, a private pharmaceutical company, from April 2015 to August 2015.

Positions